

Appendix for Rationale and Approaches to Reduce Phosphate and FGF23 Levels in CKD

Tamara Isakova, MD, MMSc,¹ Joachim H. Ix, MD, MAS,² Stuart M. Sprague, DO,³ Kalani L. Raphael, MD, MS,⁴ Linda Fried, MD, MPH,⁵ Jennifer J. Gassman, PhD,⁶ Dominic Raj, MD,⁷ Alfred K. Cheung, MD,⁴ John W. Kusek, PhD,⁸ Michael F. Flessner, MD, PhD,⁸ Myles Wolf, MD, MMSc,¹ and Geoffrey A. Block, MD.⁹

From

¹Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

²Nephrology Section, Veterans Affairs San Diego Healthcare System and Division of Nephrology and Preventive Medicine, University of California, San Diego, San Diego, CA

³NorthShore University Health System-University of Chicago, Pritzker School of Medicine, Evanston, IL

⁴Salt Lake City Veterans Affairs Healthcare System and Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT

⁵Renal Section, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA

⁶Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, OH

⁷Division of Renal Diseases and Hypertension, the George Washington University, Washington DC

⁸National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

⁹Denver Nephrology, Denver, CO

Correspondence should be addressed to:

Tamara Isakova, MD, MMSc 633 N. St. Clair St., Suite 18-083, Chicago, IL 60611;

Phone: (312) 503-6921

Fax: (312) 503-5656

Email: tamara.isakova@northwestern.edu

The CKD Optimal Management with BInders and Nicotinamide (COMBINE) Study

Group

U01 Consortium Steering Committee Chair: Linda Fried, MD, MPH; U01 Consortium Principal Investigators: Jennifer J. Gassman, PhD; Dominic Raj, MD; Myles Wolf, MD, MMSc; Joachim Ix, MD, MAS; and Alfred K. Cheung, MD; U01 Consortium Co-Principal Investigators: Tamara Isakova, MD, MMSc; Geoff Block, MD and Kalani L. Raphael, MD, MS; NIDDK Project Officers: Michael F. Flessner, MD, PhD and John W. Kusek, PhD.

Data Coordinating Center: Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, (Principal Investigator) Jennifer J. Gassman, PhD.

Participating Clinical Centers: George Washington University, Washington, DC, (Principal Investigator) Dominic Raj, MD; Northwestern University Feinberg School of Medicine, Chicago, IL, (Principal Investigator) Myles Wolf, MD, MMSc; NorthShore University Health System Evanston Hospital, Evanston, IL, (Principal Investigator) Stuart Sprague, DO; University of California San Diego, VA San Diego Healthcare System, San Diego, CA, (Principal Investigator) Joachim Ix, MD, MAS; Denver Nephrology, Denver, CO, (Principal Investigator) Geoffrey Block, MD; University of Utah and Salt Lake City VA Health Care System, Salt Lake City, UT, (Principal Investigator) Kalani L. Raphael, MD, MS.

Additional MRI Sites: University of Colorado, Denver, CO, (Principal Investigator) Michel Chonchol, MD; National Institutes of Health Clinical Center, Bethesda, MD, (Principal Investigator) Ahmed M. Gharib, MB, ChB.

Cardiac MRI Core: 4D Lab – Advanced Image Data Analysis, Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, (Principal Investigator) James C. Carr, MD.

Renal MRI Core: Center for Advanced Imaging, Department of Radiology, Evanston

Northwestern Healthcare, Evanston, IL, (Principal Investigator) Pottumarthi V. Prasad, PhD.

Central FGF23 and Biomarker Laboratory: Department of Laboratory Medicine, University of Washington, Seattle, WA, (Principal Investigator) Andrew N. Hoofnagle, MD, PhD.

Central Chemistry Laboratory: Spectra Clinical Research, Rockleigh, NJ.

Central Drug Distribution Center: Fisher Clinical Services, Mount Prospect, IL.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Project Office:

Michael F. Flessner, MD, PhD; John W. Kusek, PhD.